Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The purpose of this study is to determine if the new orally active iron chelator, ICL670, is as safe as deferoxamine in preventing accumulation of iron in the body while a patient is undergoing repeated blood transfusions.
Epistemonikos ID: 6bbb072e00e30dc962772b3bbd239056a2df0890
First added on: May 04, 2024